Zinc-α2-glycoprotein: A proliferative factor for breast cancer? In vitro study and molecular mechanisms

Delort,Laetitia; Perrier,Stéphane; Dubois,Virginie; Billard,Hermine; Mracek,Tomas; Bing,Chen; Vasson,Marie-Paule; Caldefie-Chézet,Florence

doi:10.3892/or.2013.2311

Zinc-α2-glycoprotein: A proliferative factor for breast cancer? In vitro study and molecular mechanisms

Authors:
- Laetitia Delort
- Stéphane Perrier
- Virginie Dubois
- Hermine Billard
- Tomas Mracek
- Chen Bing
- Marie-Paule Vasson
- Florence Caldefie-Chézet
View Affiliations

Affiliations: Clermont University, University of Auvergne, UFR Pharmacy, Laboratory SVFp, F-63000 Clermont-Ferrand, France, Obesity Biology Research Unit, School of Clinical Sciences, University of Liverpool, Liverpool L69 3GA, UK
Published online on: February 27, 2013 https://doi.org/10.3892/or.2013.2311
Pages: 2025-2029

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zinc-α2-glycoprotein (ZAG) is a new adipokine whose gene expression is downregulated in obese patients. We recently reported ZAG expression in breast tumor or healthy breast tissue and detected this expression at high levels in ductal carcinoma and in normal epithelial adjacent tissue but not in normal tissue of healthy women. In the present study, we used two human breast tumor cell lines (MCF-7 and MDA-MB‑231) and one fibrocystic breast cell line (MCF‑10a) to examine whether recombinant ZAG has an effect on proliferative/apoptotic response in breast cancer cell lines. ZAG seemed to exert a proliferative effect on breast cancer cell proliferation [+11 to 27% in MCF-7 with (ZAG) = 5-20 µg/ml; +13% in MDA-MB-231 with (ZAG) = 5 µg/ml] and, on the contrary, an anti-proliferative effect in the fibrocystic breast cell line [-5 to -8% in MCF-10a with (ZAG) = 5-10 µg/ml]. ZAG was able to modulate gene and protein expression involved in the apoptotic response. However, further studies are required to fully elucidate the effects of ZAG on the proliferation of mammary cells.

View Figures

View References

1	Klein S, Wadden T and Sugerman HJ: AGA technical review on obesity. Gastroenterology. 123:882–932. 2002. View Article : Google Scholar : PubMed/NCBI
2	Lorincz AM and Sukumar S: Molecular links between obesity and breast cancer. Endocr Relat Cancer. 13:279–292. 2006. View Article : Google Scholar : PubMed/NCBI
3	Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF and Adam HO: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 12:13–21. 2001. View Article : Google Scholar
4	Chlebowski RT, Aiello E and McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol. 20:1128–1143. 2002. View Article : Google Scholar : PubMed/NCBI
5	Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR and Porter PL: Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 92:720–729. 2001. View Article : Google Scholar : PubMed/NCBI
6	Belfiore A and Frasca F: IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 13:381–406. 2008. View Article : Google Scholar : PubMed/NCBI
7	Cold S, Hansen S, Overvad K and Rose C: A woman’s build and the risk of breast cancer. Eur J Cancer. 34:1163–1174. 1998.
8	Pischon T, Nothlings U and Boeing H: Obesity and cancer. Proc Nutr Soc. 67:128–145. 2008. View Article : Google Scholar
9	Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 115:911–919. 2005. View Article : Google Scholar : PubMed/NCBI
10	Tilg H and Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 6:772–783. 2006. View Article : Google Scholar : PubMed/NCBI
11	Perrier S, Caldefie-Chezet F and Vasson MP: IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett. 583:259–265. 2009. View Article : Google Scholar : PubMed/NCBI
12	Rose DP, Komninou D and Stephenson GD: Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 5:153–165. 2004. View Article : Google Scholar : PubMed/NCBI
13	Schaffler A, Scholmerich J and Buechler C: Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 3:345–354. 2007. View Article : Google Scholar : PubMed/NCBI
14	Vona-Davis L, Howard-McNatt M and Rose DP: Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 8:395–408. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, Guillot J and Vasson MP: Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 53:484–487. 2008. View Article : Google Scholar : PubMed/NCBI
16	Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F and Vasson MP: Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer. 16:1197–1210. 2009. View Article : Google Scholar : PubMed/NCBI
17	Jarde T, Perrier S, Vasson MP and Caldefie-Chezet F: Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 47:33–43. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ and Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA. 101:2500–2505. 2004. View Article : Google Scholar : PubMed/NCBI
19	Marrades MP, Martinez JA and Moreno-Aliaga MJ: ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem. 64:61–66. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mracek T, Ding Q, Tzanavari T, Kos K, Pinkney J, Wilding J, Trayhurn P and Bing C: The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clin Endocrinol. 72:334–341. 2010. View Article : Google Scholar : PubMed/NCBI
21	Bundred NJ, Miller WR and Walker RA: An immunohistochemical study of the tissue distribution of the breast cyst fluid protein, zinc alpha 2 glycoprotein. Histopathology. 11:603–610. 1987. View Article : Google Scholar : PubMed/NCBI
22	Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A and Lopez-Otin C: Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer. 29A:1256–1260. 1993. View Article : Google Scholar : PubMed/NCBI
23	Bundred NJ, Scott WN, Davies SJ, Miller WR and Mansel RE: Zinc alpha-2 glycoprotein levels in serum and breast fluids: a potential marker of apocrine activity. Eur J Cancer. 27:549–552. 1991. View Article : Google Scholar : PubMed/NCBI
24	Sanchez LM, Vizoso F, Diez-Itza I and Lopez-Otin C: Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res. 52:95–100. 1992.PubMed/NCBI
25	Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP and Caldefie-Chezet F: Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res. 30:2919–2925. 2010.PubMed/NCBI
26	Meyer N, Kim SS and Penn LZ: The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 16:275–287. 2006. View Article : Google Scholar : PubMed/NCBI
27	Prendergast GC: Mechanisms of apoptosis by c-Myc. Oncogene. 18:2967–2987. 1999. View Article : Google Scholar : PubMed/NCBI
28	Sakamuro D, Eviner V, Elliott KJ, Showe L, White E and Prendergast GC: c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene. 11:2411–2418. 1995.PubMed/NCBI
29	Lee YJ, Galoforo SS, Berns CM, Tong WP, Kim HR and Corry PM: Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci. 110:681–686. 1997.PubMed/NCBI
30	He N, Brysk H, Tyring SK, Ohkubo I and Brysk MM: Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression. J Cell Biochem Suppl. 36:162–169. 2001. View Article : Google Scholar : PubMed/NCBI
31	Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E and Reed JC: Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat. 47:129–140. 1998. View Article : Google Scholar : PubMed/NCBI
32	Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG and Scherer PE: Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 22:6408–6423. 2003. View Article : Google Scholar
33	Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F and Gromova I: Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics. 4:492–522. 2005. View Article : Google Scholar
34	Perera CN, Spalding HS, Mohammed SI and Camarillo IG: Identification of proteins secreted from leptin stimulated MCF-7 breast cancer cells: a dual proteomic approach. Exp Biol Med. 233:708–720. 2008. View Article : Google Scholar : PubMed/NCBI